Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
|Articles|September 16, 2008
- June15 2003
- Volume 10
- Issue 11
PHARMACEUTICAL STOCKWATCH
Advertisement
Articles in this issue
about 18 years ago
CLOUDY CRYSTAL BALLabout 18 years ago
TAX LAW FOR GULLIBLEabout 18 years ago
BOND YIELDS HIT LOWabout 18 years ago
RENTAL RATES RISINGabout 18 years ago
CONFESSING THEIR SINSabout 18 years ago
KEEPING YOUR BALANCEabout 18 years ago
DID YOU KNOW?about 18 years ago
KIDS & FINANCESabout 18 years ago
THE PRESIDENT PAYSabout 18 years ago
SAY NO TO REFINANCINGAdvertisement
Related to this article
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.
Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.
Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Advertisement
Advertisement
Trending on HCPLive
1
RELIEVE-AD-PEDs: Dupilumab Sustains Adolescent Atopic Dermatitis Control at 1 Year
2
Targeting the Disease Mechanism in PFIC, With Hisamitsu Hayashi, PhD
3
Top Reason for Leaving HAE Attacks Untreated, Survey Finds
4
10 Nephrology Headlines You Missed in Q3 2026
5